company background image
BLGO

BioLargo OTCPK:BLGO Stock Report

Last Price

US$0.17

Market Cap

US$46.0m

7D

-9.4%

1Y

-10.3%

Updated

15 May, 2022

Data

Company Financials
BLGO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BLGO Stock Overview

BioLargo, Inc. invents, develops, and commercializes various platform technologies.

BioLargo Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioLargo
Historical stock prices
Current Share PriceUS$0.17
52 Week HighUS$0.29
52 Week LowUS$0.15
Beta0.00045
1 Month Change-23.47%
3 Month Change-33.51%
1 Year Change-10.31%
3 Year Change-0.17%
5 Year Change-64.13%
Change since IPO-75.40%

Recent News & Updates

Shareholder Returns

BLGOUS ChemicalsUS Market
7D-9.4%-0.8%-2.5%
1Y-10.3%-6.2%-10.4%

Return vs Industry: BLGO underperformed the US Chemicals industry which returned -6.2% over the past year.

Return vs Market: BLGO matched the US Market which returned -10.4% over the past year.

Price Volatility

Is BLGO's price volatile compared to industry and market?
BLGO volatility
BLGO Average Weekly Movement8.7%
Chemicals Industry Average Movement7.1%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: BLGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BLGO's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199127Dennis Calverthttps://www.biolargo.com

BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company’s technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services.

BioLargo Fundamentals Summary

How do BioLargo's earnings and revenue compare to its market cap?
BLGO fundamental statistics
Market CapUS$46.02m
Earnings (TTM)-US$7.08m
Revenue (TTM)US$2.53m

18.2x

P/S Ratio

-6.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLGO income statement (TTM)
RevenueUS$2.53m
Cost of RevenueUS$1.43m
Gross ProfitUS$1.10m
Other ExpensesUS$8.18m
Earnings-US$7.08m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.026
Gross Margin43.58%
Net Profit Margin-279.73%
Debt/Equity Ratio73.0%

How did BLGO perform over the long term?

See historical performance and comparison

Valuation

Is BioLargo undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


9.89x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLGO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BLGO's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: BLGO is unprofitable, so we can't compare its PE Ratio to the US Chemicals industry average.

PE vs Market: BLGO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLGO is overvalued based on its PB Ratio (9.9x) compared to the US Chemicals industry average (2.1x).


Future Growth

How is BioLargo forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


8.2%

Forecasted Materials industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioLargo has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has BioLargo performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


3.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BLGO is currently unprofitable.

Growing Profit Margin: BLGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLGO is unprofitable, but has reduced losses over the past 5 years at a rate of 3.2% per year.

Accelerating Growth: Unable to compare BLGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLGO is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (34.5%).


Return on Equity

High ROE: BLGO has a negative Return on Equity (-738.91%), as it is currently unprofitable.


Financial Health

How is BioLargo's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BLGO's short term assets ($1.8M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: BLGO's short term assets ($1.8M) exceed its long term liabilities ($716.0K).


Debt to Equity History and Analysis

Debt Level: BLGO has more cash than its total debt.

Reducing Debt: BLGO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLGO has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BLGO is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is BioLargo current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLGO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BLGO has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

19.2yrs

Average management tenure


CEO

Dennis Calvert (58 yo)

19.92yrs

Tenure

US$651,445

Compensation

Mr. Dennis P. Calvert serves as the Chairman of the Board at BioLargo, Inc. and has been its Chief Executive Officer and President since June 28, 2002. Mr. Calvert has an extensive entrepreneurial backgrou...


CEO Compensation Analysis

Compensation vs Market: Dennis's total compensation ($USD651.45K) is about average for companies of similar size in the US market ($USD770.21K).

Compensation vs Earnings: Dennis's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BLGO's management team is seasoned and experienced (19.2 years average tenure).


Board Members

Experienced Board: BLGO's board of directors are seasoned and experienced ( 15.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.


Top Shareholders

Company Information

BioLargo, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: BioLargo, Inc.
  • Ticker: BLGO
  • Exchange: OTCPK
  • Founded: 1991
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Implied Market Cap: US$46.022m
  • Shares outstanding: 267.26m
  • Website: https://www.biolargo.com

Number of Employees


Location

  • BioLargo, Inc.
  • 14921 Chestnut Street
  • Westminster
  • California
  • 92683
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.